Retour sur le congrès de l AHA 2017
|
|
- Dortha Clark
- 6 years ago
- Views:
Transcription
1 Retour sur le congrès de l AHA 2017 Paul Poirier MD, PhD, FRCPC, FACC, FAHA, FCCS Professeur Faculté de pharmacie Université Laval Responsable du programme de prévention/réadaptation cardiaque
2 Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program Kenneth W. Mahaffey, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Elisa Fabbrini, Tao Sun, Qiang Li, Mehul Desai, David R. Matthews, on behalf of the CANVAS Program collaborative group Mahaffey KW, et al. Circulation
3 Introduction Patients with type 2 diabetes mellitus (T2DM) suffer substantial morbidity and mortality from cardiovascular (CV) and renal disease 1,2 Elevated relative and absolute risks of serious outcomes have been observed for both primary and secondary prevention cohorts While the largest absolute benefits of interventions for individual patients are achieved amongst those with established CV disease (secondary prevention), the very large number of diabetes patients without overt CV disease (primary prevention) makes knowledge about the effects of therapies on first events an additional priority 1. Guariguata L, et al. Diabetes Res Clin Pract. 2014;103(2): Liyanage T, et al. Lancet. 2015;385(9981):
4 The CANVAS Program The CANagliflozin cardiovascular Assessment Study (CANVAS) Program was designed to assess the CV safety and efficacy of canagliflozin compared with placebo in a broad range of patients with T2DM 1-4 Canagliflozin reduced the relative risk of CV death, nonfatal myocardial infarction (MI), or nonfatal stroke by 14% (p = 0.02 for superiority) 4 Hospitalized heart failure and serious declines in renal function were reduced by 33% and 40%, respectively 4 An unanticipated ~2-fold increase in risk of amputation was also observed 4 By design, the CANVAS Program enrolled patients with and without prior CV disease to provide insight into the effects of canagliflozin in the primary and secondary prevention settings These analyses describe the efficacy and safety of canagliflozin separately for the primary and secondary prevention cohorts enrolled in the CANVAS Program 1. Neal B, et al. Am Heart J. 2013;166(2): Neal B, et al. Diabetes Obes Metab. 2017;19(3): Neal B, et al. Diabetes Obes Metab. 2017;19(7): Neal B, et al. N Engl J Med. 2017;377(7):
5 Efficacy and Safety Outcomes The following outcomes were evaluated in the primary and secondary prevention cohorts: CV death, nonfatal MI, or nonfatal stroke Individual components of CV death, nonfatal MI, or nonfatal stroke Hospitalization for heart failure All-cause mortality Renal composite outcome of 40% reduction in egfr, requirement for renal replacement therapy, or renal death Safety events of interest, including AEs attributable to genital infection, urinary tract infection, volume depletion events, hypoglycemia, diabetic ketoacidosis, acute pancreatitis, renal AEs, thromboembolism, cancer, fracture, and lower extremity amputation All major CV events, renal outcomes, and deaths as well as selected safety outcomes (diabetic ketoacidosis, acute pancreatitis, and fracture) were assessed by Endpoint Adjudication Committees
6 Participants Discontinuation of study drug similar with placebo and canagliflozin in the overall population (30% vs 29%) in the secondary prevention (29% vs 30%) In the primary prevention cohorts (31% vs 28%) Participant characteristics were well-balanced between treatment groups in the primary and secondary prevention cohorts
7 Outcomes in Secondary and Primary Prevention Cohorts Secondary prevention participants had higher rates of the CV composite outcome compared with the primary prevention participants There were more hospitalizations for heart failure, more deaths, and more of the composite renal outcome in the secondary prevention compared with the primary prevention group Rates of safety outcomes were not different except for lower extremity amputation and volume depletion events, which were more frequent among secondary prevention participants, and urinary tract infection, which was less common in secondary prevention participants
8 Effects of Canagliflozin on CV and Renal Outcomes The primary endpoint of CV death, nonfatal MI, or nonfatal stroke was reduced with canagliflozin compared to placebo (26.9 vs 31.5/1000 patient-years; HR 0.86, 95% CI: 0.75, 0.97; p <0.001 for noninferiority; p = 0.02 for superiority) in the total cohort 1 There was no statistical evidence of heterogeneity (p = 0.18) between the primary and secondary prevention groups There was no statistical evidence of heterogeneity between the primary and secondary prevention cohorts for hospitalization for heart failure, all-cause mortality, and the composite renal outcome (all p values for homogeneity 0.10) 1. Neal B, et al. N Engl J Med. 2017;377(7):
9 Effects of Canagliflozin Versus Placebo on CV and Mortality Outcomes Secondary prevention Primary prevention Overall population CV death, nonfatal MI, or nonfatal stroke CV death Nonfatal MI Nonfatal stroke Hospitalization for any cause Hospitalization for heart failure CV death or hospitalization for heart failure All-cause mortality Hazard ratios and 95% CIs were estimated by using Cox regression models, with stratification by trial for all canagliflozin groups combined versus placebo. *p <0.001 for noninferiority and p = 0.02 for superiority in the overall population. Patients per 1000 patient-years Number Hazard ratio of patients Canagliflozin Placebo (95% CI) p-interaction (0.72, 0.95) (0.74, 1.30) (0.75, 0.97)* (0.70, 1.06) (0.60, 1.43) (0.72, 1.06) (0.63, 0.99) (0.73, 2.00) (0.69, 1.05) (0.67, 1.16) (0.59, 1.61) (0.71, 1.15) (0.84, 0.99) (0.88, 1.15) (0.88, 1.00) (0.51, 0.90) (0.35, 1.15) (0.52, 0.87) (0.65, 0.92) (0.58, 1.19) (0.67, 0.91) (0.75, 1.07) (0.58, 1.07) (0.74, 1.01) Favors Canagliflozin Favors Placebo
10 Effects of Canagliflozin Versus Placebo on Renal Outcomes Secondary prevention Primary prevention Overall population Progression of albuminuria Number of patients Patients per 1000 patient-years Canagliflozin Placebo Hazard ratio (95% CI) p-interaction (0.67, 0.82) (0.60, 0.79) (0.67, 0.79) 40% reduction in egfr, renal replacement therapy, or renal death 40% reduction in egfr Renal replacement therapy Renal death* Hazard ratios and 95% CIs were estimated by using Cox regression models, with stratification by trial for all canagliflozin groups combined versus placebo. *Incidence rates and hazard ratios not calculated due to the small number of events (0.44, 0.79) (0.39, 1.02) (0.47, 0.77) (0.44, 0.81) (0.37, 1.00) (0.47, 0.78) (0.18, 2.64) (0.25, 3.53) (0.30, 1.97) Favors Canagliflozin Favors Placebo 0.85
11 CV Death, Nonfatal MI, or Nonfatal Stroke Secondary Prevention Primary Prevention
12 CV Death Secondary Prevention Primary Prevention
13 Hospitalization for Heart Failure Secondary Prevention Primary Prevention
14 Effects of Canagliflozin on Safety Outcomes Rates of AEs including genital infections, urinary tract infections, fractures, diabetic ketoacidosis and acute pancreatitis were not statistically different between treatment groups in the primary and secondary prevention participants The AE profile for canagliflozin compared with placebo was consistent in the primary and secondary prevention participants (all interaction p values 0.07)
15 Secondary prevention Primary prevention Overall population Male genital infection Female genital infection* Effects of Canagliflozin Versus Placebo on Safety Outcomes Patients per 1000 patient-years Number of patients Canagliflozin Placebo Hazard ratio (95% CI) p-interaction (2.72, 4.98) (2.60, 6.10) (2.12, 7.48) (2.51, 9.24) Urinary tract infection* Lower-extremity amputation All fracture Low-trauma fracture Diabetic ketoacidosis (0.75, 1.29) (0.94, 1.74) (1.43, 3.00) (0.70, 3.29) (0.99, 1.59) (0.94, 1.75) (0.94, 1.61) (0.86, 1.75) (0.56, 38.03) (0.40, 6.16) *For these adverse events, the annualized event rates are reported with data from CANVAS alone through January 7, 2014, because, after this time, only serious adverse events or adverse events leading to discontinuation were collected. In CANVAS-R, only serious adverse events or adverse events leading to discontinuation were collected. Owing to the differences between the 2 trials in methods of collection of the data, an integrated analysis of these adverse events is not possible Favors Canagliflozin Favors Placebo
16 Risk Differences for CV, Renal, and Amputation Outcomes Secondary prevention Primary prevention Overall population CV death, nonfatal MI, or nonfatal stroke Hospitalization for heart failure 40% reduction in egfr, renal replacement therapy, or renal death Lower extremity amputation Number of patients Patients per 1000 patient-years Canagliflozin Placebo Excess number of active patients experiencing the event in 1000 patients over 5 years (95% CI) ( 63, 9) ( 20, 23) ( 42, 4) ( 33, 7) ( 18, 2) ( 25, 7) ( 33, 8) ( 25, 0.5) ( 27, 8) (11, 31) ( 3, 13) (8, 22) Benefit Harm
17 Discussion The CANVAS Program included patients with established CV disease (~2/3) and patients at risk for CV disease (~1/3) Overall CV and renal event rates were higher in secondary prevention compared with primary prevention participants Canagliflozin provided numerically greater reductions in CV and renal outcomes in secondary prevention participants, with no statistical evidence of heterogeneity in relative reductions between groups Rates of common AEs were generally similar between cohorts The rate of lower extremity amputation was ~3-fold higher in the secondary prevention compared with the primary prevention group A statistically significant 2-fold increase in amputation was observed with canagliflozin versus placebo in the secondary prevention group; the result was statistically similar result between groups in the primary prevention cohort, which only reported 33 events Until further information is available on the potential mechanism for amputations with canagliflozin, caution should be used in patients at risk for amputations
18 Benefits and Risks The balance of CV and renal benefits compared with the major safety event of amputations was evaluated by calculating the number of patients with events prevented or caused over 5 years for 1000 treated patients As expected, there were numerically more events prevented in the secondary prevention compared with the primary prevention participants In both cohorts, the number of excess amputation events was numerically lower than the number of prevented cardiorenal outcomes
19 Conclusions In the CANVAS Program that evaluated patients with T2DM and elevated CV risk, participants with prior CV events (secondary prevention) compared with those without prior CV events (primary prevention) had greater absolute rates of CV, renal, and death outcomes Canagliflozin reduced CV and renal outcomes overall, with no statistical evidence of heterogeneity of canagliflozin effects between the primary and secondary prevention participants
20 POISE-2 PeriOperative ISchemic Evaluation-2 Trial Aspirin in patients with previous percutaneous coronary intervention (PCI) undergoing noncardiac surgery: The POISE-2 PCI Substudy Dr. Michelle M. Graham University of Alberta and Mazankowski Alberta Heart Institute, Edmonton, Canada on behalf of POISE-2 Investigators
21 Background Globally >200 million noncardiac surgeries annually 10 million suffer major vascular complication increased mortality, hospitalization, costs Providers commonly encounter patients with previous PCI undergoing surgery increased risk of major perioperative complications Uncertainty remains regarding effects of aspirin in patients with prior PCI who are undergoing noncardiac surgery
22 POISE-2 POISE-2 randomized 10,010 patients having noncardiac surgery to aspirin vs. placebo aspirin did not prevent primary outcome of death/mi but increased risk of major bleeding Steering Committee did not expect randomization of patients with prior PCI and did not pre-specify PCI subgroup analysis however, 470 prior PCI patients were randomized We therefore undertook analyses to determine whether subgroup effect was present among patients with prior PCI
23 Methods Design blinded 2 X 2 factorial RCT Aspirin versus placebo and clonidine versus placebo Eligibility criteria undergoing noncardiac surgery, 45 yrs, at risk of vascular complication Excluded patients BMS <6 weeks before surgery DES <1 year before surgery took aspirin within 72 hrs before surgery
24 Methods 2 aspirin strata initiation stratum continuation stratum Intervention aspirin/placebo (200 mg) just before surgery continued daily (100 mg) 30 days in initiation stratum and 7 days in continuation stratum Primary outcome death or nonfatal MI at 30 days
25 Outcome definitions MI universal definition of MI Major bleed bleeding event Hb 70 g/l and 2 units RBCs; Hb drop 50 g/l and 2 units of RBCs; 4 units of RBCs within 24 hr period; intervention (e.g., embolization); or retroperitoneal, intraspinal, or intraocular bleed
26 Prior PCI subgroup 470 patients with prior PCI randomized at 82 centres in 21 countries 234 randomized to aspirin 236 randomized to placebo 30-day follow-up 99.9% complete
27 PCI characteristics PCI characteristics N (%) Bare-metal stent 255 (54.3) drug-eluting stent 119 (25.3) unknown type of stent 55 (11.7) no stent 41 (8.7) PCI with uncertainty regarding whether stent was used median duration from PCI to noncardiac surgery 2 (0.4%) 64 months (IQR )
28 Outcomes Outcome Aspirin n/n (%) Placebo n/n (%) HR (95% CI) Interaction P Value Death/MI overall trial No Prior PCI Prior PCI 351/4998 (7.0) 337/4764 (7.1) 14/234 (6.0) 355/5012 (7.1) 328/4776 (6.9) 27/236 (11.4) 0.99 ( ) 1.03 ( ) 0.50 ( ) 0.036
29 Outcomes Outcome Aspirin n/n (%) Placebo n/n (%) HR (95% CI) Interaction P Value Death/MI overall trial No Prior PCI Prior PCI 351/4998 (7.0) 337/4764 (7.1) 14/234 (6.0) 355/5012 (7.1) 328/4776 (6.9) 27/236 (11.4) 0.99 ( ) 1.03 ( ) 0.50 ( ) MI overall trial No Prior PCI Prior PCI 309/4998 (6.2) 297/4764 (6.2) 12/234 (5.1) 315/5012 (6.3) 289/4776 (6.1) 26/236 (11.0) 0.98 ( ) 1.03 ( ) 0.44 ( ) 0.021
30 Death/MI in prior PCI patients
31 Outcomes Outcome Aspirin n/n (%) Placebo n/n (%) HR (95% CI) Interaction P Value Major bleeding overall trial No Prior PCI Prior PCI 230/4998 (4.6) 222/4764 (4.7) 8/234 (3.4) 189/5012 (3.8) 180/4776 (3.8) 9/236 (3.8) 1.22 ( ) 1.24 ( ) 0.85 ( ) 0.50
32 Conclusions For every 1000 patients with prior PCI, perioperative aspirin will prevent 59 MIs but cause 8 major bleeds Among those with prior PCI undergoing noncardiac surgery, preoperative aspirin may be more likely to benefit than harm patients
33 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults American College of Cardiology Foundation and American Heart Association, Inc.
34 Systematic Review Questions on High BP in Adults Question Number Question 1 Is there evidence that self-directed monitoring of BP and/or ambulatory BP monitoring are superior to office-based measurement of BP by a healthcare worker for 1) preventing adverse outcomes for which high BP is a risk factor and 2) achieving better BP control? 2 What is the optimal target for BP lowering during antihypertensive therapy in adults? 3 In adults with hypertension, do various antihypertensive drug classes differ in their comparative benefits and harms? 4 In adults with hypertension, does initiating treatment with antihypertensive pharmacological monotherapy versus initiating treatment with 2 drugs (including fixed-dose combination therapy), either of which may be followed by the addition of sequential drugs, differ in comparative benefits and/or harms on specific health outcomes? BP indicates blood pressure.
35 2017 Hypertension Guideline Classification of BP
36 Definition of High BP COR LOE Recommendation for Definition of High BP I B-NR BP should be categorized as normal, elevated, or stage 1 or 2 hypertension to prevent and treat high BP.
37 Categories of BP in Adults* BP Category SBP DBP Normal <120 mm Hg and <80 mm Hg Elevated mm Hg and <80 mm Hg Hypertension Stage mm Hg or mm Hg Stage mm Hg or 90 mm Hg *Individuals with SBP and DBP in 2 categories should be designated to the higher BP category. BP indicates blood pressure (based on an average of 2 careful readings obtained on 2 occasions, as detailed in DBP, diastolic blood pressure; and SBP systolic blood pressure.
38 Prevalence of Hypertension Based on 2 SBP/DBP Thresholds* SBP/DBP 130/80 mm Hg or Self-Reported Antihypertensive Medication SBP/DBP 140/90 mm Hg or Self- Reported Antihypertensive Medication Overall, crude 46% 32% Men (n=4717) Women (n=4906) Men (n=4717) Women (n=4906) Overall, age-sex 48% 43% 31% 32% adjusted Age group, y % 19% 11% 10% % 44% 33% 27% % 63% 53% 52% % 75% 64% 63% % 85% 71% 78% Race-ethnicity Non-Hispanic White 47% 41% 31% 30% Non-Hispanic Black 59% 56% 42% 46% Non-Hispanic Asian 45% 36% 29% 27% Hispanic 44% 42% 27% 32% The prevalence estimates have been rounded to the nearest full percentage. *130/80 and 140/90 mm Hg in 9623 participants ( 20 years of age) in NHANES BP cutpoints for definition of hypertension in the present guideline. BP cutpoints for definition of hypertension in JNC 7. Adjusted to the 2010 age-sex distribution of the U.S. adult population. BP indicates blood pressure; DBP, diastolic blood pressure; NHANES, National Health and Nutrition Examination Survey; and SBP, systolic blood pressure.
39 2017 Hypertension Guideline Measurement of BP
40 Accurate Measurement of BP in the Office COR I LOE C-EO Recommendation for Accurate Measurement of BP in the Office For diagnosis and management of high BP, proper methods are recommended for accurate measurement and documentation of BP.
41 Out-of-Office and Self-Monitoring of BP COR I LOE A SR Recommendation for Out-of-Office and Self- Monitoring of BP Out-of-office BP measurements are recommended to confirm the diagnosis of hypertension and for titration of BP-lowering medication, in conjunction with telehealth counseling or clinical interventions. SR indicates systematic review.
42 Corresponding Values of SBP/DBP for Clinic, HBPM, Daytime, Nighttime, and 24- Hour ABPM Measurements Clinic HBPM Daytime ABPM Nighttime ABPM 24-Hour ABPM 120/80 120/80 120/80 100/65 115/75 130/80 130/80 130/80 110/65 125/75 140/90 135/85 135/85 120/70 130/80 160/ /90 145/90 140/85 145/90 ABPM indicates ambulatory blood pressure monitoring; BP, blood pressure; DBP diastolic blood pressure; HBPM, home blood pressure monitoring; and SBP, systolic blood pressure.
43 2017 Hypertension Guideline Treatment of High BP
44 Blood Pressure (BP) Thresholds and Recommendations for Treatment and Follow-Up BP thresholds and recommendations for treatment and follow-up Normal BP (BP <120/80 mm Hg) Elevated BP (BP /<80 mm Hg) Stage 1 hypertension (BP /80-89 mm Hg) Stage 2 hypertension (BP 140/90 mm Hg) Promote optimal lifestyle habits Nonpharmacologic therapy (Class I) Clinical ASCVD or estimated 10-y CVD risk 10%* No Yes Reassess in 1 y (Class IIa) Reassess in 3 6 mo (Class I) Nonpharmacologic therapy (Class I) Nonpharmacologic therapy and BP-lowering medication (Class I) Nonpharmacologic therapy and BP-lowering medication (Class I) Reassess in 3 6 mo (Class I) Reassess in 1 mo (Class I)
45 1 y (Class IIa) 3 6 mo (Class I) therapy (Class I) BP-lowering medication (Class I) BP-lowering medication (Class I) Reassess in 3 6 mo (Class I) Reassess in 1 mo (Class I) BP goal met No Assess and optimize adherence to therapy Yes Reassess in 3 6 mo (Class I) Consider intensification of therapy Colors correspond to Class of Recommendation in Table 1. *Using the ACC/AHA Pooled Cohort Equations. Note that patients with DM or CKD are automatically placed in the highrisk category. For initiation of RAS inhibitor or diuretic therapy, assess blood tests for electrolytes and renal function 2 to 4 weeks after initiating therapy. Consider initiation of pharmacological therapy for stage 2 hypertension with 2 antihypertensive agents of different classes. Patients with stage 2 hypertension and BP 160/100 mm Hg should be promptly treated, carefully monitored, and subject to upward medication dose adjustment as necessary to control BP. Reassessment includes BP measurement, detection of orthostatic hypotension in selected patients (e.g., older or with postural symptoms), identification of white coat hypertension or a white coat effect, documentation of adherence, monitoring of the response to therapy, reinforcement of the importance of adherence, reinforcement of the importance of treatment, and assistance with treatment to achieve BP target.
46 2017 Hypertension Guideline Hypertension in Patients With Comorbidities
47 Stable Ischemic Heart Disease COR I I LOE SBP: B-R DBP: C-EO SBP: B-R DBP: C-EO Recommendations for Treatment of Hypertension in Patients With Stable Ischemic Heart Disease (SIHD) In adults with SIHD and hypertension, a BP target of less than 130/80 mm Hg is recommended. Adults with SIHD and hypertension (BP 130/80 mm Hg) should be treated with medications (e.g., GDMT beta blockers, ACE inhibitors, or ARBs) for compelling indications (e.g., previous MI, stable angina) as first-line therapy, with the addition of other drugs (e.g., dihydropyridine CCBs, thiazide diuretics, and/or mineralocorticoid receptor antagonists) as needed to further control hypertension.
48 Stable Ischemic Heart Disease (cont.) COR I IIa IIb LOE B-NR B-NR C-EO Recommendations for Treatment of Hypertension in Patients With Stable Ischemic Heart Disease (SIHD) In adults with SIHD with angina and persistent uncontrolled hypertension, the addition of dihydropyridine CCBs to GDMT beta blockers is recommended. In adults who have had a MI or acute coronary syndrome, it is reasonable to continue GDMT beta blockers beyond 3 years as long-term therapy for hypertension. Beta blockers and/or CCBs might be considered to control hypertension in patients with CAD (without HFrEF) who had an MI more than 3 years ago and have angina.
49 Diabetes Mellitus COR I I IIb LOE SBP: B-R SR DBP: C-EO A SR B-NR Recommendations for Treatment of Hypertension in Patients With DM In adults with DM and hypertension, antihypertensive drug treatment should be initiated at a BP of 130/80 mm Hg or higher with a treatment goal of less than 130/80 mm Hg. In adults with DM and hypertension, all first-line classes of antihypertensive agents (i.e., diuretics, ACE inhibitors, ARBs, and CCBs) are useful and effective. In adults with DM and hypertension, ACE inhibitors or ARBs may be considered in the presence of albuminuria. SR indicates systematic review.
50 2017 Hypertension Guideline Summary of BP Thresholds and Goals for Pharmacological Therapy Plan of Care for Hypertension
51 BP Thresholds for and Goals of Pharmacological Therapy in Patients With Hypertension According to Clinical Conditions Clinical Condition(s) BP Threshold, mm Hg BP Goal, mm Hg General Clinical CVD or 10-year ASCVD risk 10% 130/80 <130/80 No clinical CVD and 10-year ASCVD risk <10% 140/90 <130/80 Older persons ( 65 years of age; noninstitutionalized, 130 (SBP) <130 (SBP) ambulatory, community-living adults) Specific comorbidities Diabetes mellitus 130/80 <130/80 Chronic kidney disease 130/80 <130/80 Chronic kidney disease after renal transplantation 130/80 <130/80 Heart failure 130/80 <130/80 Stable ischemic heart disease 130/80 <130/80 Secondary stroke prevention 140/90 <130/80 Secondary stroke prevention (lacunar) 130/80 <130/80 Peripheral arterial disease 130/80 <130/80 ASCVD indicates atherosclerotic cardiovascular disease; BP, blood pressure; CVD, cardiovascular disease; and SBP, systolic blood pressure.
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program Kenneth W. Mahaffey, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Greg Fulcher,
More informationHYPERTENSION: ARE WE GOING TOO LOW?
HYPERTENSION: ARE WE GOING TOO LOW? George L. Bakris, M.D.,F.A.S.N.,F.A.S.H., F.A.H.A. Professor of Medicine Director, ASH Comprehensive Hypertension Center University of Chicago Medicine Chicago, IL USA
More informationBlood Pressure Treatment in 2018
Blood Pressure Treatment in 2018 Jay D. Geoghagan, MD, FACC Disclosures: None 1 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management
More informationUsing the New Hypertension Guidelines
Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in
More informationPharmacy Updates in Primary Care. Nathan Lamberton Assistant Professor
Pharmacy Updates in Primary Care January 31 st, 2018 Nathan Lamberton Assistant Professor David N. Ombengi Associate Professor First Metformin, Then? AR is a 57 year old African American male with a PMH
More informationThe New Hypertension Guidelines
The New Hypertension Guidelines Joseph Saseen, PharmD Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Disclosure Joseph Saseen reports no conflicts
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationHypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program
Hypertension: JNC-7 Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! Reference Card
More informationHypertension. Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute
Hypertension Does it Matter What Medications We Use? Nishant K. Sekaran, M.D. M.Sc. Intermountain Heart Institute Hypertension 2017 Classification BP Category Systolic Diastolic Normal 120 and 80 Elevated
More informationHypertension Guidelines 2017
Hypertension Guidelines 2017 (American College of Cardiology and the American Heart Association) In 1977, the 1st comprehensive guideline for detection, evaluation, and management of high BP was published,
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More information2/11/2019 CLINICAL IMPLEMENTATION OF THE UPDATED BP GUIDELINES DUALITY OF INTEREST
CLINICAL IMPLEMENTATION OF THE UPDATED BP GUIDELINES George L. Bakris, M.D.,F.A.S.N., F.A.H.A. Professor of Medicine Director, Am Heart Assoc. Comprehensive Hypertension Center University of Chicago Medicine
More information2017 ACC/AHA/AAPA/ABC/ACPM/AGS/
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults American College of Cardiology Foundation and
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationEgyptian Hypertension Guidelines
Egyptian Hypertension Guidelines 2014 Egyptian Hypertension Guidelines Dalia R. ElRemissy, MD Lecturer of Cardiovascular Medicine Cairo University Why Egyptian Guidelines? Guidelines developed for rich
More informationHypertension and Cardiovascular Disease
Hypertension and Cardiovascular Disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationHYPERTENSION: UPDATE 2018
HYPERTENSION: UPDATE 2018 From the Cardiologist point of view Richard C Padgett, MD I have no disclosures HYPERTENSION ALWAYS THE ELEPHANT IN THE EXAM ROOM BUT SOMETIMES IT CHARGES HTN IN US ~78 million
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationTreating Hypertension in 2018: What Makes the Most Sense Today?
Treating Hypertension in 2018: What Makes the Most Sense Today? Daniel Blanchard, MD Professor of Medicine UC San Diego Cardiovascular Center La Jolla, California 1 2 Speaker Disclosures Consultant and/or
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationGuidelines PATHOLOGY: FATAL PERIOPERATIVE MI NON-PMI N = 25 PMI N = 42. Prominent Dutch Cardiovascular Researcher Fired for Scientific Misconduct
PATHOLOGY: FATAL PERIOPERATIVE MI NON-PMI N = 25 PMI N = 42 Preoperative, Intraoperative, and Postoperative Factors Associated with Perioperative Cardiac Complications in Patients Undergoing Major Noncardiac
More informationManaging HTN in the Elderly: How Low to Go
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
More informationInvokana (canagliflozin) NEW INDICATION REVIEW
Invokana (canagliflozin) NEW INDICATION REVIEW Introduction Brand name: Invokana Generic name: Canagliflozin Pharmacological class: Sodium-glucose cotransporter 2 (SGLT2) inhibitor Strength and Formulation:
More informationNew Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD
New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD None Disclosures Objectives Understand trend in blood pressure clinical practice guidelines
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationDapagliflozin and cardiovascular outcomes in type 2
EARN 3 FREE CPD POINTS diabetes Leader in digital CPD for Southern African healthcare professionals Dapagliflozin and cardiovascular outcomes in type 2 diabetes Introduction People with type 2 diabetes
More informationSESSION 5 2:20 3:35 pm
SESSION 2:2 3:3 pm Strategies to Reduce Cardiac Risk for Noncardiac Surgery SPEAKER Lee A. Fleisher, MD Presenter Disclosure Information The following relationships exist related to this presentation:
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationNew Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationBlood Pressure LIMBO How Low To Go?
Blood Pressure LIMBO How Low To Go? Joseph L. Kummer, MD, FACC Bryan Heart Spring Conference April 21 st, 2018 Hypertension Epidemiology Over a billion people have hypertension Major cause of morbidity
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationHypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD?
Hypertension and Diabetes Should we be SPRINTING or Reaching an ACCORD? Suzanne Oparil, MD Distinguished Professor of Medicine, Professor of Cell, Developmental and Integrative Biology Director, Vascular
More informationSystolic Blood Pressure Intervention Trial (SPRINT)
09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP
More informationHypertension targets: sorting out the confusion. Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town
Hypertension targets: sorting out the confusion Brian Rayner, Division of Nephrology and Hypertension, University of Cape Town Historical Perspective The most famous casualty of this approach was the
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationPressure Drop: The Latest Guidelines on Treating Hypertension
Pressure Drop: The Latest Guidelines on Treating Hypertension Eric J MacLaughlin, Pharm.D. Joseph J Saseen, Pharm.D. Target Audience: Pharmacists ACPE#: 0202-0000-18-050-L01-P Activity Type: Application-based
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationBlood Pressure Treatment Goals
Blood Pressure Treatment Goals Kenneth Izuora, MD, MBA, FACE Associate Professor UNLV School of Medicine November 18, 2017 Learning Objectives Discuss the recent studies on treating hypertension Review
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More informationObjectives. Describe results and implications of recent landmark hypertension trials
Hypertension Update Daniel Schwartz, MD Assistant Professor of Medicine Associate Medical Director of Heart Transplantation Temple University School of Medicine Disclosures I currently have no relationships
More informationWhat s the evidence, why do guidelines differ, and what should the GP do?
What s the evidence, why do guidelines differ, and what should the GP do? Richard McManus Barcelona 2018 Overview What is hypertension? How should blood pressure be measured/diagnosed? What should we be
More informationThe Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI
The Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI Interventional Cardiologist Cardiovascular Institute of the South Director of Cardiovascular Services St. Charles Parish
More informationHTN talk_l Davis_ /28/2018
1 2 GUIDELINES PUBLISHED AHEAD OF PRINT NOV 13, 2017 = SAME DAY AS PUBLIC PRESENTATION LESLIE L DAVIS, PHD, RN, ANP-BC, FPCNA, FAANP, FAHA The New Guidelines Have Been Published! Whelton PK, Carey RM,
More informationNone. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to:
2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) James W. Shaw, MD Memorial Lecture
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More informationInt. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences
Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationTiming of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationClinical Controversies in Perioperative Medicine
Clinical Controversies in Perioperative Medicine Hugo Quinny Cheng, MD Division of Hospital Medicine University of California, San Francisco Cardiac Evaluation: New Guidelines A 70-y.o. man with progressive
More informationHEART HEALTH UPDATE 2018
HEART HEALTH UPDATE 2018 Shilpa Kshatriya, MD, FACC Heartland Cardiology, PA 02/20/18 Heart Disease and Stroke Statistics Cardiovascular disease, is theeading cause of death in the US, accounts for nearly
More informationHypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations
Hypertension in the Era of ACC/AHA: Practice Changing Evidence and Recommendations Gerald W. Smetana, M.D., MACP Division of General Medicine Beth Israel Deaconess Medical Center Professor of Medicine
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationPerioperative Cardiology Consultations for Noncardiac Surgery Ischemic Heart Disease
2012 대한춘계심장학회 Perioperative Cardiology Consultations for Noncardiac Surgery Ischemic Heart Disease 울산의대울산대학병원심장내과이상곤 ECG CLASS IIb 1. Preoperative resting 12-lead ECG may be reasonable in patients with
More informationManagement of Lipid Disorders and Hypertension: Implications of the New Guidelines
Management of Lipid Disorders and Hypertension Management of Lipid Disorders and Hypertension: Implications of the New Guidelines Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine
More informationHypertension Management: A Moving Target
9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,
More informationLong-Term Care Updates
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationMPharmProgramme. Hypertension (HTN)
MPharmProgramme Hypertension (HTN) Slide 1 of 30 Overview Definition Prevalence Type Causes Diagnosis Management Patients perspective Slide 2 of 30 Definition It is not a disease! So what is it? What two
More informationHypertension and the SPRINT Trial: Is Lower Better
Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,
More information2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with American Association for Thoracic Surgery, American
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationHypertension Putting the Guidelines into Practice
Hypertension 2017 Putting the Guidelines into Practice Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or
More informationNew Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationSupplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationPreoperative Cardiac Evaluation:
Preoperative Cardiac Evaluation: The New Guidelines Hugo Quinny Cheng, MD Division of Hospital Medicine University of California, San Francisco Disclosures No financial relationships with pharmaceutical
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationNew Hypertension Guidelines. Kofi Osei, MD
New Hypertension Guidelines Kofi Osei, MD None Disclosures Objectives The new blood pressure definitions and cardiovascular risk The role to time and location in the diagnosis of hypertension Apply evidence-based
More informationSummary, Scope, BP Classification, BP thresholds and Targets
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/ PCNA Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults Summary, Scope, BP Classification, BP thresholds
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationSelf-measured blood pressure monitoring (SMBP)
Self-measured blood pressure monitoring (SMBP) Michael Rakotz, MD, FAHA FAAFP Vice President, Improving Health Outcomes, American Medical Association Assistant Clinical Professor, Department of Family
More informationhypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationUpdate in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP
Update in Cardiology Pharmacologic Management of Cardiovascular Risk Christopher C. Roe, MSN, ACNP Objectives 1. Verbalize understanding of new pharmacologic guidelines in the treatment of hypertension
More information2019 Update on Recent Guideline Releases for Diabetes, Hypertension, and Dyslipidemia: Can We, Please, All Just Get on the Same Page?!
2019 Update on Recent Guideline Releases for Diabetes, Hypertension, and Dyslipidemia: Can We, Please, All Just Get on the Same Page?! Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM Assistant Professor,
More informationWe are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients.
Richard Roetzheim, MD, MSPH is Professor and Chair, Department of Family Medicine at the University of South Florida Morsani College of Medicine. Dr. Roetzheim has considerable experience leading NIH funded
More informationHYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS
HYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS Michael J. Scalese, PharmD, BCPS, CACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 14, 2018 DISCLOSURE/CONFLICT OF INTEREST
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition ACOFP - The Heart of the Matter - An Evidence
More informationHypertension JNC 8 (2014)
Hypertension JNC 8 (2014) Renewed: February 2018 Updated: February 2015 Comparison of Seventh Joint National Committee (JNC 7) vs. Eighth Joint National Committee (JNC 8) Hypertension Guidelines Methodology
More information5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016
Outpatient Stroke Management Sheila Smith MD May 5, 2016 1 Management of Outpatient Stroke Objectives Review blood pressure management post stroke Review antithrombotic therapy Review statin therapy Discuss
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationΣυμπεράσματα από τις νέες μελέτες για την αρτηριακή υπέρταση (SPRINT,PATHAY 2,HOPE 3)
Συμπεράσματα από τις νέες μελέτες για την αρτηριακή υπέρταση (SPRINT,PATHAY 2,HOPE 3) Χάρης Γράσσος MD,FESC,PhD,EHS Διευθυντής Καρδιολόγος Γ.Ν.Α ΚΑΤ Visiting Professor University of Bolton U.K New England
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationYuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China
What Can We Learn from the Observational Studies and Clinical Trials of Prehypertension? Yuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China At ARIC visit 4
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationManagement of Hypertension in special groups. DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University
Management of Hypertension in special groups BY DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University AGENDA SPECIAL GROUPS SPECIFIC DRUDS FOR SPECIAL GROUPS TARGET BP FOR SPECIAL GROUPS:
More informationMetoprolol Succinate SelokenZOC
Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic
More information